Gilead cash pile burns hole in investors' pockets
San Francisco
IN THE drug industry's biggest-ever period for deals, one wildly successful company with a multibillion-dollar war chest has been oddly silent. So what's Gilead Sciences Inc waiting for?
Drugmakers have done US$179 billion worth of mergers and acquisitions so far this year, on pace to top last year's US$221 billion record. Gilead has stayed on the sidelines, holding US$10.6 billion in cash and equivalents. The company reports second quarter earnings on Tuesday, and M&A will be on shareholders' minds.
"Investors are getting anxious," said Bloomberg Intelligence analyst Asthika Goonewarde. After the company's explosive revenue gr…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Billionaires selling cheap stuff get richer from inflation pain
Amazon to push cashierless shopping tech into more third-party stores, while backing off itself